ReviewFrontiers in immunology2025
Mini-review: Serum immunoglobulins and MASLD.
Review in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
With the development of society and the economy, metabolic dysfunction-associated steatotic liver disease (MASLD) has become a major chronic disease in contemporary society. Finding a safe, effective, and economical diagnostic method is essential for the prevention of MASLD. Serum immunoglobulin is a protein produced by the B cells after the body is stimulated by an external antigen or pathogen. It is very interesting and valuable to explore the relationship between serum immunoglobulins and MASLD. Unfortunately, only a small number of studies have explored the relationship between serum immunoglobulins and MASLD. Therefore, we review the research progress of serum immunoglobulins in MASLD. At the same time, we also discuss the shortcomings of these studies. We hope this review will provide experience and reference for the prevention of MASLD in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.